Article thumbnail

The Appearance and Modulation of Osteocyte Marker Expression during Calcification of Vascular Smooth Muscle Cells

By Dongxing Zhu, Neil Charles Wallace Mackenzie, José Luis Millán, Colin Farquharson and Vicky Elizabeth MacRae
Topics: Research Article
Publisher: Public Library of Science
OAI identifier: oai:pubmedcentral.nih.gov:3096630
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles

Citations

  1. (2005). A generalized skeletal hyperostosis in two siblings caused by a novel mutation in the SOST gene.
  2. (1996). Adhesive properties of isolated chick osteocytes in vitro.
  3. (1996). Characterization and cloning of the E11 antigen, a marker expressed by rat osteoblasts and osteocytes.
  4. (1988). Characterization of endosteal osteoblastic cells isolated from mouse caudal vertebrae.
  5. (2005). Chondrogenesis mediatedby PPi depletion promotes spontaneous aortic calcification in NPP12/2 mice.
  6. (2001). Dentin matrix protein 1 is predominantly expressed in chicken and rat osteocytes but not in osteoblasts.
  7. (2006). E11/ gp38 selective expression in osteocytes: regulation by mechanical strain and role in dendrite elongation.
  8. (2004). Elevated extracellular calcium levels induce smooth muscle cell matrix mineralization in vitro.
  9. (1999). Germline deletion of the nucleoside triphosphate pyrophosphohydrolase (NTPPPH) plasma cell membrane glycoprotein-1 (PC-1) produces abnormal calcification of periarticular tissues.
  10. (2009). Increased bone mass, altered trabecular architecture and modified growth plate organization in the growing skeleton of SOCS2 deficient mice.
  11. (2010). Inhibition of PHOSPHO1 activity results in impaired skeletal mineralization during limb development of the chick.
  12. (2008). Interrelation of coronary calcification, myocardial ischemia, and outcomes in patients with intermediate likelihood of coronary artery disease: a combined positron emission tomography/computed tomography study.
  13. (2006). Loss of DMP1 causes rickets and osteomalacia and identifies a role for osteocytes in mineral metabolism.
  14. Lowik CW (2005) Bone morphogenic proteins and their antagonists: the sclerostin paradigm.
  15. (2004). Matrix metalloproteinases (MMPs) safeguard osteoblasts from apoptosis during transdifferentiation into osteocytes: MT1-MMP maintains osteocyte viability.
  16. (2008). Matrix mineralization as a trigger for osteocyte maturation.
  17. (2003). Mechanical loading stimulates dentin matrix protein 1 (DMP1) expression in osteocytes in vivo.
  18. (1999). Medial localization of mineralization-regulating proteins in association with Mo ¨nckeberg’s sclerosis: evidence for smooth muscle cell-mediated vascular calcification.
  19. (1999). Microtubules are potential regulators of growth-plate chondrocyte differentiation and hypertrophy.
  20. (2005). Msx2 promotes cardiovascular calcification by activating paracrine Wnt signals.
  21. (1998). Mutation in Npps in a mouse model of ossification of the posterior longitudinal ligament of the spine.
  22. (2003). Mutations in Enpp1 are associated with ‘idiopathic’ infantile arterial calcification.
  23. (2007). Novel inhibitors of alkaline phosphatase suppress vascular smooth muscle cell calcification.
  24. (2007). Osteoblast autonomous Pi regulation via Pit1 plays a role in bone mineralization.
  25. (2007). Osteocytes as dynamic multifunctional cells.
  26. (2008). Osteocytes, mechanosensing and Wnt signaling.
  27. (2001). PC-1 nucleoside triphosphate pyrophosphohydrolase deficiency in idiopathic infantile arterial calcification.
  28. (2010). Proteomics characterization of extracellular space components in the human aorta.
  29. (2009). Regulation of podoplanin/PA2.26 antigen expression in tumour cells. Involvement of calpain-mediated proteolysis.
  30. (1995). Regulators of chondrocyte differentiation in tibial dyschondroplasia: an in vivo and in vitro study.
  31. (1999). Responses of bone cells to biomechanical forces in vitro.
  32. (2006). Role of the sodium-dependent phosphate cotransporter, Pit-1, in vascular smooth muscle cell calcification.
  33. (2010). Sclerostin binds and regulates the activity of cysteine-rich protein 61.
  34. (2001). Smooth muscle cell phenotypic transition associated with calcification: upregulation of Cbfa1 and downregulation of smooth muscle lineage markers.
  35. (2005). Smooth muscle cells deficient in osteopontin have enhanced susceptibility to calcification in vitro.
  36. (2008). Targeted deletion of the sclerostin gene in mice results in increased bone formation and bone strength.
  37. (2001). The E11 osteoblastic lineage marker is differentially expressed during fracture healing.
  38. (2009). The promise of sclerostin inhibitioin for the treatment of osteoporosis.
  39. (2006). The restricted potential for recovery of growth plate chondrogenesis and longitudinal bone growth following exposure to pro-inflammatory cytokines.
  40. (2007). The vascular biology of calcification.
  41. (2009). Time lapse imaging techniques for comparison of mineralization dynamics in primary murine osteoblasts and the late osteoblast/early osteocyte-like cell line MLO-A5. Cells Tissues Organs 189:
  42. (2002). Tissuenonspecific alkaline phosphatase and plasma cell membrane glycoprotein-1 are central antagonistic regulators of bone mineralization.
  43. (2008). Transglutaminase 2 is central to induction of the arterial calcification program by smooth muscle cells.
  44. (2008). Upregulation of alkaline phosphatase and pyrophosphate hydrolysis: potential mechanism for uremic vascular calcification.
  45. (2004). Vascular calcification: mechanisms and clinical ramifications.
  46. (2008). Vascular calcification: pathobiology of a multifaceted disease.